<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03572790</url>
  </required_header>
  <id_info>
    <org_study_id>Pruc_7d</org_study_id>
    <nct_id>NCT03572790</nct_id>
  </id_info>
  <brief_title>Effects of Seven Day Prucalopride Administration in Healthy Volunteers</brief_title>
  <official_title>The Effect of Seven Day Prucalopride Administration on Emotional Processing in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate whether seven days administration of the serotonin receptor
      subtype 4 (5-HT4) partial agonist prucalopride has effects on emotional processing and neural
      activity in healthy volunteers, compared to placebo administration. Using an experimental
      medicine approach, the effects of prucalopride on cognitive biomarkers of antidepressant
      action will be characterised. In a double-blind design, participants will be randomised to
      receive seven days administration of either prucalopride (1mg daily) or placebo. All
      participants will come for a Screening visit, Research Visit One (including an MRI scan) and
      Research Visit Two (including measures of emotional processing and non-emotional cognition).
      The primary study hypothesis is that seven-day prucalopride administration will have positive
      effects on emotional processing and reward sensitivity. A secondary hypothesis is that
      seven-day prucalopride administration will alter non-emotional cognition. Finally, the study
      will test the hypothesis that seven day prucalopride administration will alter neural
      activity during an emotional faces task and a memory task.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2018</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomly allocated to one of two groups (prucalopride or placebo). Participants in the prucalopride group will receive 1mg once daily for seven days. Participants in the placebo group will receive a lactose placebo once daily for seven days. Note that the study is not assessing the safety or efficacy of prucalopride, rather it is using prucalopride to assess the behavioural and neural effects of 5-HT4 partial agonists.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recognition of positive and negative facial expressions</measure>
    <time_frame>Completed on Day 7</time_frame>
    <description>Accuracy to recognise positive and negative facial expressions (anger, disgust, fear, happy , sad, surprise)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance on Auditory Verbal Learning Task (AVLT)</measure>
    <time_frame>Completed on Day 7</time_frame>
    <description>Accuracy on AVLT (number of items recalled across blocks)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neural response to emotional faces</measure>
    <time_frame>Completed on Day 6</time_frame>
    <description>Blood Oxygen Level Dependent (BOLD) signal in a network including the amygdala, anterior cingulate cortex, and orbitofrontal cortex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neural response to novel vs repeated scenes</measure>
    <time_frame>Completed on Day 6</time_frame>
    <description>BOLD signal to scenes that have previously been seen compared to novel scenes in a network including the hippocampus and parahippocampal regions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reward sensitivity</measure>
    <time_frame>Completed on Day 7</time_frame>
    <description>Sensitivity to reward as measured by the Probabilistic Instrumental Learning Task (PILT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorisation, recall, and recognition of emotional words</measure>
    <time_frame>Completed on Day 7</time_frame>
    <description>Accuracy and reaction time to categorise positive and negative descriptor words; number of words correctly (hits) and incorrectly (false alarms) recalled and recognised</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vigilance to fearful and happy faces on the Facial Dot Probe Task (FDOT)</measure>
    <time_frame>Completed on Day 7</time_frame>
    <description>Vigilance derived from reaction time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting state connectivity</measure>
    <time_frame>Completed on Day 6</time_frame>
    <description>Resting state connectivity (using resting state fMRI) including the default mode network, salience network, affective network, and limbic system, identified via correlations between spontaneous BOLD activity in spatially independent regions while participants are not actively engaged in an experimental task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative and global cerebral blood flow</measure>
    <time_frame>Completed on Day 6</time_frame>
    <description>Arterial spin labelling (ASL) global and cerebral blood flow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual short term memory on the Oxford Memory Test (OMT)</measure>
    <time_frame>Completed on Day 7</time_frame>
    <description>Proportion of correct probe selections, absolute error for probe location, reaction time, and proportion of misbinding errors</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Molecular Mechanisms of Pharmacological Action</condition>
  <condition>Depression</condition>
  <condition>Depressive Disorder</condition>
  <condition>Mood Disorders</condition>
  <condition>Mental Disorders</condition>
  <condition>Antidepressive Agents</condition>
  <condition>Cognition</condition>
  <arm_group>
    <arm_group_label>Prucalopride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prucalopride</intervention_name>
    <description>1mg prucalopride capsule, once daily for seven days</description>
    <arm_group_label>Prucalopride</arm_group_label>
    <other_name>Resolor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Lactose placebo capsule, once daily for seven days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant is willing and able to give informed consent for participation in the
             study

          -  Male or female

          -  Aged 18-40 years

          -  Sufficiently fluent English to understand and complete the task

          -  Right handed

          -  Body Mass Index in the range of 18-30

          -  Not currently taking any medications (except the contraceptive pill)

        Exclusion Criteria:

          -  Not fluent in English

          -  Any past or current Axis 1 DSM-V psychiatric disorder

          -  Current usage of psychoactive medication (except the contraceptive pill, the
             Depo-Provera injection or the progesterone implant)

          -  Current usage of any medication that will influence the MRI scan

          -  Current or past history of drug or alcohol dependency

          -  Currently pregnant or breastfeeding

          -  Study visits due to take place during the pre-menstrual week (female participants
             asked details of their menstrual cycle to schedule the study outside this week)

          -  Not right handed

          -  Body Mass Index outside the range of 18-30

          -  History of cardiac, thyroid, or liver problems

          -  An autoimmune disorder

          -  Current, or a history of, gastro-intestinal disorder or irritable bowel syndrome

          -  Epilepsy

          -  Known lactate deficiency or any other problem absorbing lactose, galactose, or glucose

          -  Participation in a study which uses the same computer tasks as those used in the
             present study

          -  Participation in a study that involves the use of a medication within the last three
             months

          -  Smoker &gt; 5 cigarettes per day

          -  Typically drinks &gt; 6 caffeinated drinks per day

          -  Any contraindication to MRI scanning (e.g. metal objects in the body, pacemakers,
             significant claustrophobia)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susannah E Murphy, DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susannah E Murphy, DPhil</last_name>
    <phone>01865 618313</phone>
    <phone_ext>+44</phone_ext>
    <email>susannah.murphy@psych.ox.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lucy C Wright, MSc</last_name>
    <phone>01865 618319</phone>
    <phone_ext>+44</phone_ext>
    <email>lucy.wright@psych.ox.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Oxford</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7JX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.perloxford.org</url>
    <description>Psychopharmacology and Emotion Research Laboratory</description>
  </link>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 7, 2018</study_first_submitted>
  <study_first_submitted_qc>June 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2018</study_first_posted>
  <last_update_submitted>August 16, 2019</last_update_submitted>
  <last_update_submitted_qc>August 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Oxford</investigator_affiliation>
    <investigator_full_name>drsusannahmurphy</investigator_full_name>
    <investigator_title>Senior Research Fellow</investigator_title>
  </responsible_party>
  <keyword>5-HT4</keyword>
  <keyword>Prucalopride</keyword>
  <keyword>Resolor</keyword>
  <keyword>Functional Magnetic Resonance Imaging (fMRI)</keyword>
  <keyword>Emotional Processing</keyword>
  <keyword>Healthy Volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prucalopride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 16, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT03572790/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT03572790/ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 16, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT03572790/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

